The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes
Open accessAbstract
BACKGROUND: An impaired glomerular filtration rate (GFR) leads to end-stage renal disease and increases the risks of cardiovascular disease and death. Persons with type 1 diabetes are at high risk for kidney disease, but there are no interventions that have been proved to prevent impairment of the GFR in this population. METHODS: In the Diabetes Control and Complications Trial (DCCT), 1441 persons with type 1 diabetes were randomly assigned to 6.5 years of intensive diabetes therapy aimed at achieving near-normal glucose concentrations or to conventional diabetes therapy aimed at preventing hyperglycemic symptoms. Subsequently, 1375 participants were followed in the observational Epidemiology of Diabetes Interventions and Complications (EDIC) study. Serum creatinine levels were measured annually throughout the course of the two studies. The GFR was estimated with the use of the Chronic Kidney Disease Epidemiology Collaboration formula. We analyzed data from the two studies to determine the long-term effects of intensive diabetes therapy on the risk of impairment of the GFR, which was defined as an incident estimated GFR of less than 60 ml per minute per 1.73 m(2) of body-surface area at two consecutive study visits. RESULTS: Over a median follow-up period of 22 years in the combined studies, impairment of the GFR developed in 24 participants assigned to intensive therapy and in 46 assigned to conventional therapy (risk reduction with intensive therapy, 50%; 95% confidence interval, 18 to 69; P=0.006). Among these participants, end-stage renal disease developed in 8 participants in the intensive-therapy group and in 16 in the conventional-therapy group. As compared with conventional therapy, intensive therapy was associated with a reduction in the mean estimated GFR of 1.7 ml per minute per 1.73 m(2) during the DCCT study but during the EDIC study was associated with a slower rate of reduction in the GFR and an increase in the mean estimated GFR of 2.5 ml per minute per 1.73 m(2) (P<0.001 for both comparisons). The beneficial effect of intensive therapy on the risk of an impaired GFR was fully attenuated after adjustment for glycated hemoglobin levels or albumin excretion rates. CONCLUSIONS: The long-term risk of an impaired GFR was significantly lower among persons treated early in the course of type 1 diabetes with intensive diabetes therapy than among those treated with conventional diabetes therapy. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; DCCT/EDIC ClinicalTrials.gov numbers, NCT00360815 and NCT00360893.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Insulin alone was used to lower blood glucose in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) study of type 1 diabetes, while a variety of agents were used in clinical trials of type 2 diabetes, supporting the conclusion that lowering blood glucose itself helps prevent CKD and its progression.”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [53]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In both T1D or T2D, lower achieved levels of HbA1c < 7% ( < 53 mmol/mol) versus 8% -9% (64 -75 mmol/mol) reduce risk of overall microvascular complications, including nephropathy and retinopathy, and macrovascular complications in some RCTs. 189 -193”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [191]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In RCTs, targeting lower HbA1c values using glucose-lowering medications has been proven to reduce risks of microvascular diabetes complications (i.e., kidney disease, retinopathy, neuropathy) and, in some studies, also macrovascular diabetes complications (i.e., cardiovascular events).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [191]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intensive lowering of blood glucose with the goal of achieving near-normoglycemia has been shown in large, randomized studies to delay the onset and progression of albuminuria and reduce eGFR in people with type 1 diabetes (54,55) and type 2 diabetes (1,56,57).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [55]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Intensive lowering of blood glucose with the goal of achieving near-normoglycemia has been shown in large, randomized studies to delay the onset and progression of albuminuria and reduce eGFR in people with type 1 diabetes (52,53) and type 2 diabetes (1,(54)(55)(56)(57)(58)(59).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“However, the bene fi ts of more-stringent glycemic control (i.e., lower HbA1c targets) compared with less-stringent glycemic control (i.e., higher HbA1c targets) manifest over many years of treatment. 191,248,249”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [191]
The cited source says what the claim attributes to it.
In the citing paper
“In randomized clinical trials, it has taken a number of years for bene fi ts of intensive glycemic control to manifest as improved clinical outcomes. 190,191,234,245,246,248,256”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [191]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Self-citationA Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citationBrenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Self-citationA Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 568
Mundinger, T. O., Mei, Q., Foulis, A. K., Fligner, C. L., Hull, R. L., & Taborsky, G. J. (2016) · Diabetes · doi:10.2337/db16-0284 · Cited by 84
Wu, D. C., Hester, J., Nadig, S. N., Zhang, W., Trzonkowski, P., Gray, D. W. R., Hughes, S. J., Johnson, P., & Wood, K. J. (2013) · Transplantation · doi:10.1097/tp.0b013e31829fa271 · Cited by 83
Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives
Lv, M., Chen, Z., Hu, G., & Li, Q. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.007 · Cited by 84
Improvements in the Management of Diabetic Nephropathy
Dounousi, E. C., Duni, Α., Leivaditis, K., Vaios, V., Eleftheriadis, T., & Liakopoulos, V. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.119 · Cited by 83
Endothelial Function in Pre-diabetes, Diabetes and Diabetic Cardiomyopathy: A Review
Ciccone, M. M. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000364 · Cited by 77
Realising the long-term promise of insulin therapy: the DCCT/EDIC study
Nathan, D. M. (2021) · Diabetologia · doi:10.1007/s00125-021-05397-4 · Cited by 83
Solini, A., Penno, G., Bonora, E., Fondelli, C., Orsi, E., Trevisan, R., Vedovato, M., Cavalot, F. L., Cignarelli, M., Morano, S., et al. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12381 · Cited by 74
Pathomthongtaweechai, N., & Chutipongtanate, S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110655 · Cited by 72
Ku, E., Glidden, D. V., Johansen, K. L., Sarnak, M. J., Tighiouart, H., Grimes, B. A., & Hsu, C. (2014) · Kidney International · doi:10.1038/ki.2014.376 · Cited by 75
Orchard, T. J., Lyons, T. J., Cleary, P. A., Braffett, B. H., Maynard, J., Cowie, C. C., Gubitosi‐Klug, R., Way, J. F., Anderson, K., Barnie, A., et al. (2013) · Diabetes Care · doi:10.2337/dc12-2661 · Cited by 71
Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016121372 · Cited by 72
Current Challenges in Diabetic Nephropathy: Early Diagnosis and Ways to Improve Outcomes
Kim, S. S., Kim, J. H., & Kim, I. J. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.2.245 · Cited by 73
Bera, A., Das, F., Ghosh‐Choudhury, N., Mariappan, M. M., Kasinath, B. S., & Choudhury, G. G. (2017) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00081.2017 · Cited by 71
Glycated hemoglobin and outcomes in patients with advanced diabetic chronic kidney disease
Kuo, I.-C., Lin, H. Y.-H., Niu, S.-W., Hwang, D.-Y., Lee, J.-J., Tsai, J.-C., Hung, C.-C., Hwang, S.-J., & Chen, H.-C. (2016) · Scientific Reports · doi:10.1038/srep20028 · Cited by 70
Bjornstad, P., Snell‐Bergeon, J. K., Rewers, M., Jalal, D. I., Chonchol, M. B., Johnson, R. J., & Maahs, D. M. (2013) · Diabetes Care · doi:10.2337/dc13-0631 · Cited by 70
Improved prognosis of diabetic nephropathy in type 1 diabetes
Andrésdóttir, G., Jensen, M. L., Carstensen, B., Parving, H., Hovind, P. H., Hansen, T. W., & Rossing, P. R. (2014) · Kidney International · doi:10.1038/ki.2014.206 · Cited by 71
On Behalf of the Brazilian Type 1 Diabetes Study Group (BrazDiab1SG), Viana, L. V., Gomes, M. B., Zajdenverg, L., Pavin, E. J., & Azevedo, M. J. (2016) · Trials · doi:10.1186/s13063-016-1207-6 · Cited by 65
Prevalence and Management of Diabetic Nephropathy in Western Countries
Satirapoj, B., & Adler, S. G. (2015) · Kidney Diseases · doi:10.1159/000382028 · Cited by 71
Insulin sensitivity and complications in type 1 diabetes: New insights
Bjornstad, P. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i1.8 · Cited by 66
Urva, S., Quinlan, T., Landry, J., Martin, J. A., & Loghin, C. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01012-2 · Cited by 70
Circulating Vitamin D Metabolites and Kidney Disease in Type 1 Diabetes
de Boer, I. H., Sachs, M. C., Cleary, P. A., Hoofnagle, A. N., Lachin, J. M., Molitch, M. E., Steffes, M. W., Sun, W., Zinman, B., & Brunzell, J. D. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2852 · Cited by 66
2023 Guidelines on the management of patients with diabetes - a position of Diabetes Poland
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Borys, S., Budzynski, A. Z., Cyganek, K., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G. J., et al. (2023) · Current Topics in Diabetes · doi:10.5114/ctd/160061 · Cited by 72
Measured GFR in Routine Clinical Practice—The Promise of Dried Blood Spots
Bjornstad, P., Karger, A. B., & Maahs, D. M. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.09.003 · Cited by 72
Uric Acid and Diabetic Nephropathy Risk
Mauer, M. S., & Doria, A. (2018) · Contributions to nephrology · doi:10.1159/000484284 · Cited by 63
Chronic kidney disease in patients with diabetes mellitus
Nordheim, E., & Jenssen, T. G. (2021) · Endocrine Connections · doi:10.1530/ec-21-0097 · Cited by 74
Conway, B. R., Manoharan, D., Manoharan, D., Jenks, S. J., Dear, J. W., McLachlan, S., Strachan, M. W. J., & Price, J. F. (2012) · Kidney International · doi:10.1038/ki.2012.218 · Cited by 62
Past Decline Versus Current eGFR and Subsequent Mortality Risk
Naimark, D. M. J., Grams, M. E., Matsushita, K., Black, C., Drion, I., Fox, C. S., Inker, L. A., Ishani, A., Jee, S. H., Kitamura, A., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015060688 · Cited by 62
Bebu, I., Braffett, B. H., Orchard, T. J., Lorenzi, G. M., Lachin, J. M., & the DCCT/EDIC Research Group (2019) · Diabetes Care · doi:10.2337/dc18-1613 · Cited by 62
Self-citationAntioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl
Rojas-Rivera, J. E., Ortíz, A., & Egido, J. (2012) · International Journal of Nephrology · doi:10.1155/2012/321714 · Cited by 62
Diabetic nephropathy in type 1 diabetes: has the outlook improved since the 1980s?
Marshall, S. M. (2012) · Diabetologia · doi:10.1007/s00125-012-2606-1 · Cited by 61
Diabetic kidney disease in children and adolescents
Afkarian, M. (2014) · Pediatric Nephrology · doi:10.1007/s00467-014-2796-5 · Cited by 64
Effects of High Glucose and Lipotoxicity on Diabetic Podocytes
Nakamichi, R., Hayashi, K., & Itoh, H. (2021) · Nutrients · doi:10.3390/nu13010241 · Cited by 60
SKUPIEN, J. K., Warram, J. H., Niewczas, M. A., Gohda, T., Malecki, M. T., Mychaleckyj, J. C., Gałecki, A. T., & Królewski, A. S. (2014) · Diabetes Care · doi:10.2337/dc13-1983 · Cited by 59
Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives
Rossing, P. R., Persson, F., & Frimodt‐Møller, M. (2018) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2018.02.007 · Cited by 62
Yokoyama, H., Araki, S., Kawai, K., Yamazaki, K., Tomonaga, O., Shirabe, S., & Maegawa, H. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000521 · Cited by 56
Orlov, S., Cherney, D. Z. I., Pop-Busui, R., Lovblom, L. E., Ficociello, L. H., Smiles, A. M., Warram, J. H., Krolewski, A. S., & Perkins, B. A. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11441114 · Cited by 57
Clinical therapeutic strategies for early stage of diabetic kidney disease
Kitada, M. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i3.342 · Cited by 57
Holt, S. K., Lopushnyan, N. A., Hotaling, J. M., Sarma, A. V., Dunn, R. L., Cleary, P. A., Braffett, B. H., Gatcomb, P., Martin, C. L., Herman, W. H., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1317 · Cited by 57
Gubitosi‐Klug, R., Sun, W., Cleary, P. A., Braffett, B. H., Aiello, L. P., Das, A., Tamborlane, W. V., & Klein, R. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.4606 · Cited by 56
Recent advances in managing and understanding diabetic nephropathy
Tang, S. C. W., Chan, G. C. W., & Lai, K. N. (2016) · F1000Research · doi:10.12688/f1000research.7693.1 · Cited by 56
Obesity and kidney disease in type 1 and 2 diabetes: an analysis of the National Diabetes Audit
Hill, C. J., Cardwell, C. R., Maxwell, A. P., Young, R. J., Matthews, B. B., O'Donoghue, D. J., & Fogarty, D. G. (2013) · QJM · doi:10.1093/qjmed/hct123 · Cited by 54
Effect of Insulin on ACE2 Activity and Kidney Function in the Non-Obese Diabetic Mouse
Riera, M., Márquez, E., Clotet, S., Gimeno, J., Roca-Ho, H., Lloreta, J., Juanpere-Rodero, N., BATLLE, D. C., Pascual, J., & Soler, M. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084683 · Cited by 53
Genetics and ESKD Disparities in African Americans
Umeukeje, E. M., & Young, B. A. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.06.006 · Cited by 53
VEGF and angiopoietins in diabetic glomerulopathy: How far for a new treatment?
Dei, A., & Gnudi, L. (2012) · Metabolism · doi:10.1016/j.metabol.2012.04.004 · Cited by 52
Slowing progression of chronic kidney disease
Drawz, P. E., & Rosenberg, M. E. (2013) · Kidney International Supplements · doi:10.1038/kisup.2013.80 · Cited by 51
Cleary, P. A., Braffett, B. H., Orchard, T. J., Lyons, T. J., Maynard, J., Cowie, C. C., Gubitosi‐Klug, R., Way, J. F., Anderson, K., & Barnie, A. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0316 · Cited by 52
Piscitelli, P. A., Viazzi, F. C., Fioretto, P., Giorda, C. B., Ceriello, A., Genovese, S., Russo, G. T., Guida, P., Pontremoli, R., & Cosmo, S. D. (2017) · Scientific Reports · doi:10.1038/s41598-017-03551-w · Cited by 52
Improved Glycemic Control and Risk of ESRD in Patients with Type 1 Diabetes and Proteinuria
SKUPIEN, J. K., Warram, J. H., Smiles, A. M., Gałecki, A. T., Stanton, R. C., & Królewski, A. S. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013091002 · Cited by 51
Clinical and pathological factors associated with progression of diabetic nephropathy
Liang, S., Cai, G., & Chen, X. (2017) · Nephrology · doi:10.1111/nep.13182 · Cited by 52
Shao, Y., Xu, X.-X., Li, Y., Qi, X., Wang, K., Wu, Y., & Meng, X. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.08.035 · Cited by 50
Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes
Molitch, M. E., Gao, X., Bebu, I., de Boer, I. H., Lachin, J. M., Paterson, A. D., Perkins, B. A., Saenger, A. K., Steffes, M. W., & Zinman, B. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14831218 · Cited by 51
KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD
Mottl, A. K., Alicic, R. Z., Argyropoulos, C., Brosius, F. C., Mauer, M. S., Molitch, M. E., Nelson, R. G., Perreault, L., & Nicholas, S. B. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.09.010 · Cited by 60
Early Electrophysiological Abnormalities and Clinical Neuropathy
Hyllienmark, L., Alstrand, N., Jönsson, B., Ludvigsson, J., Cooray, G., & Wahlberg-Topp, J. (2013) · Diabetes Care · doi:10.2337/dc12-2226 · Cited by 52
Ding, Q., Gao, Z., Chen, K., Zhang, Q., Hu, S., & Zhao, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.883410 · Cited by 49
Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction?
Bianchi, C., Miccoli, R., & Prato, S. D. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0371-2 · Cited by 47
Melmer, A., & Laimer, M. W. (2016) · Endocrine development · doi:10.1159/000439364 · Cited by 53
Mottl, A. K., Buse, J. B., Ismail-Beigi, F., Sigal, R. J., Pedley, C. F., Papademetriou, V., Simmons, D. L., Katz, L., Mychaleckyj, J. C., & Craven, T. E. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06200518 · Cited by 48
Fu, J., Shinjo, T., Li, Q., St-Louis, R., Park, K., Yu, M. G., Yokomizo, H., Simão, F., Huang, Q., Wu, I., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.155260 · Cited by 51
Vu, T. C., Nutt, J. G., & Holford, N. H. G. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04208.x · Cited by 47
DNA methylation age calculators reveal association with diabetic neuropathy in type 1 diabetes
Roshandel, D., Chen, Z., Canty, A. J., Bull, S. B., Natarajan, R. D., & Paterson, A. D. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00840-6 · Cited by 48
Hung, A. M., Roumie, C. L., Greevy, R. A., Liu, X., Grijalva, C. G., Murff, H. J., & Griffin, M. R. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3432 · Cited by 46
The generation of pancreatic β-cell spheroids in a simulated microgravity culture system
Tanaka, H., Tanaka, S., Sekine, K., Kita, S., Okamura, A., Takebe, T., Zheng, Y., Ueno, Y., Tanaka, J., & Taniguchi, H. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.04.003 · Cited by 47
Management of type 2 diabetes in chronic kidney disease
Triozzi, J. L., Gregg, L. P., Virani, S. S., & Navaneethan, S. D. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002300 · Cited by 47
Novel drugs and intervention strategies for the treatment of chronic kidney disease
Heerspink, H. J. L., & de Zeeuw, D. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12195 · Cited by 46
Longitudinal Changes in Estimated and Measured GFR in Type 1 Diabetes
de Boer, I. H., Sun, W., Cleary, P. A., Lachin, J. M., Molitch, M. E., Zinman, B., & Steffes, M. W. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013050557 · Cited by 45
He, C. (2019) · Oxford University Press eBooks · doi:10.1093/med/9780190611620.003.0028 · Cited by 44
Chen, D., Wang, M., Shang, X. C., Liu, X., Liu, X., Ge, T., Ren, Q., Ren, X., Song, X., Xu, H., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109040 · Cited by 46
Novel Biomarkers for the Progression of Diabetic Nephropathy: Soluble TNF Receptors
Gohda, T., & Tomino, Y. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0385-9 · Cited by 44
The Impact of Hypoglycemia on the Cardiovascular System
Yang, S., Park, K., & Zhou, Y.-J. (2015) · Angiology · doi:10.1177/0003319715623400 · Cited by 45
Glycemic Control as Primary Prevention for Diabetic Kidney Disease
MacIsaac, R. J., Jerums, G., & Ekinci, E. I. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.11.003 · Cited by 43
Insulin Pump Therapy is Equally Effective and Safe in Elderly and Young Type 1 Diabetes Patients
Matejko, B., Cyganek, K., Katra, B., Galicka-Latała, D., Grzanka, M., Malecki, M. T., & Klupa, T. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.254 · Cited by 43
Toxic stress, inflammation and symptomatology of chronic complications in diabetes
Downs, C. A., & Faulkner, M. S. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i4.554 · Cited by 42
Pacilli, A., Viazzi, F. C., Fioretto, P., Giorda, C. B., Ceriello, A., Genovese, S., Russo, G. T., Guida, P., Pontremoli, R., Cosmo, S. D., et al. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2873 · Cited by 42
Self-citationYan, Y., Liu, H., Abedini, A., Sheng, X., Palmer, M., Li, H., & Suszták, K. (2024) · Nature Communications · doi:10.1038/s41467-024-45295-y · Cited by 40
Preventing diabetes complications
Templer, S., Abdo, S., & Wong, T. (2024) · Internal Medicine Journal · doi:10.1111/imj.16455 · Cited by 52
Bächle, C., Lange, K., Stahl‐Pehe, A., Castillo, K., Scheuing, N., Holl, R. W., Giani, G., & Rosenbauer, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131027 · Cited by 41
Long-term diabetes complications after pancreas transplantation
Jenssen, T. G., Hartmann, A., & Birkeland, K. I. (2017) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000436 · Cited by 41
Childhood risk factors for adulthood chronic kidney disease
Stern-Zimmer, M., Calderon‐Margalit, R., Skorecki, K. L., & Vivante, A. (2020) · Pediatric Nephrology · doi:10.1007/s00467-020-04611-6 · Cited by 42
Insulin Therapy in Type 2 Diabetes Mellitus
Leahy, J. L. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.004 · Cited by 41
Management of traditional risk factors for the development and progression of chronic kidney disease
Lo, R. H., Narasaki, Y., Lei, S., & Rhee, C. M. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad101 · Cited by 40
Salinero-Fort, M. Á., Andrés-Rebollo, F. J. S., de Burgos‐Lunar, C., Gómez‐Campelo, P., Chico-Moraleja, R. M., López‐de‐Andrés, A., Jiménez‐García, R., & MADIABETES Group (2015) · PLoS ONE · doi:10.1371/journal.pone.0122030 · Cited by 40
Present and Future in the Treatment of Diabetic Kidney Disease
Quiroga, B., Arroyo, D., & de Arriba, G. (2015) · Journal of Diabetes Research · doi:10.1155/2015/801348 · Cited by 42
Treating diabetic nephropathy—still an unresolved issue
Cooper, M. E. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.125 · Cited by 40
Cardoso, C. R. L., Leite, N. C., Salles, G. C., Ferreira, M. T., & Salles, G. F. (2017) · Diabetologia · doi:10.1007/s00125-017-4484-z · Cited by 41
Lee, C.-L., Chen, C., Wu, M., & Tsai, S. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622319898370 · Cited by 42
Wexler, D. J., de Boer, I. H., Ghosh, A., Younes, N., Bebu, I., Inzucchi, S. E., McGill, J. B., Mudaliar, S., Schade, D., Steffes, M. W., et al. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.1487 · Cited by 39
Genetic and epigenetic background of diabetic kidney disease
Sandholm, N., Dahlström, E. H., & Groop, P. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1163001 · Cited by 39
Baldwin, D., & Apel, J. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0339-7 · Cited by 39
Four-and-a-Half LIM Domains Protein 2 Is a Coactivator of Wnt Signaling in Diabetic Kidney Disease
Li, S., Huang, P., Tarng, D., Lin, T.-P., Yang, W.-C., Chang, Y.-H., Yang, A., Lin, C., Yang, M., Chen, J., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014100989 · Cited by 38
Orchard, T. J., Sun, W., Cleary, P. A., GENUTH, S. M., Lachin, J. M., McGee, P., Paterson, A. D., Raskin, P., Anbinder, Y., & Levy, A. P. (2013) · Diabetes · doi:10.2337/db13-0256 · Cited by 38
Królewski, A. S., & Bonventre, J. V. (2012) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2012.07.002 · Cited by 38
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 44
National outcomes of kidney transplantation from deceased diabetic donors
Cohen, J. B., Bloom, R. D., Reese, P. P., Porrett, P. M., Forde, K. A., & Sawinski, D. L. (2015) · Kidney International · doi:10.1038/ki.2015.325 · Cited by 37
Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes
Pena, M. J., de Zeeuw, D., Mischak, H., Jankowski, J., Oberbauer, R. W., Woloszczuk, W., Benner, J., Dallmann, G., Mayer, B., Mayer, G. J., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv252 · Cited by 39
Strict blood pressure control associates with decreased mortality risk by APOL1 genotype
Ku, E., Lipkowitz, M. S., Appel, L. J., Parsa, A., Gassman, J., Glidden, D. V., Smogorzewski, M. J., & Hsu, C. (2016) · Kidney International · doi:10.1016/j.kint.2016.09.033 · Cited by 37
Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects
Satirapoj, B. (2017) · Kidney Diseases · doi:10.1159/000471765 · Cited by 37
Renal complications of diabetes
Min, T., Stephens, M. W., Kumar, P. R. G., & Chudleigh, R. A. (2012) · British Medical Bulletin · doi:10.1093/bmb/lds030 · Cited by 40
Epidemiological characteristics of diabetic kidney disease in Taiwan
Wang, J., Yen, F., Lin, K., Shin, S., Hsu, Y., & Hsu, C. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13668 · Cited by 34
Control of type 1 diabetes mellitus and shift work
Young, J. A., Waclawski, E., Young, J. A., & Spencer, J. (2012) · Occupational Medicine · doi:10.1093/occmed/kqs176 · Cited by 36
What's Preventing Us from Preventing Type 2 Diabetes?
FRADKIN, J. E., Roberts, B. T., & Rodgers, G. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1208169 · Cited by 35
Metadata
- Authors
- The DCCT/EDIC Research Group
- Affiliations
- University of Washington (US)
- Corresponding author
- The DCCT/EDIC Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-12-22
- Volume
- 365
- Issue
- 25
- Pages
- 2366-2376
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3270008
- OpenAlex
- W2141495158
- Cited by
- 568
- References
- 28
- Citations by year
- 2026: 4 · 2025: 24 · 2024: 20 · 2023: 34 · 2022: 29 · 2021: 32 · 2020: 40 · 2019: 27 · 2018: 35 · 2017: 35 · 2016: 45 · 2015: 54 · 2014: 58 · 2013: 65 · 2012: 61
- FWCI
- 46.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- Abbott Laboratories
- Eli Lilly and Company
- Sanofi
- Northwestern University
- University of Washington
- Novo Nordisk
- Genentech
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK087726, RC4DK090766, R01DK088762)
- National Center for Research Resources
- Division of Diabetes, Endocrinology, and Metabolic Diseases
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, intensive diabetes therapy, glomerular filtration rate, diabetic nephropathy, end-stage renal disease, glycemic control, HbA1c, albuminuria, chronic kidney disease
- MeSH terms
- Adult, Creatinine, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Female, Follow-Up Studies, Glomerular Filtration Rate, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Kidney Failure, Chronic, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
